Skip to main content
Larimar Therapeutics, Inc. logo

Larimar Therapeutics, Inc. — Investor Relations & Filings

Ticker · LRMR ISIN · US98885E1038 LEI · 529900NCBZHTTJV6HX73 US Professional, scientific and technical activities
Open in API
Filings indexed 666 across all filing types
Latest filing 2016-07-01 Director's Dealing
Country US United States of America
Listing US LRMR

About Larimar Therapeutics, Inc.

https://larimartx.com/

Larimar Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. The company utilizes a proprietary intracellular delivery platform to design fusion proteins that deliver therapeutic molecules to targets within cells. Its lead product candidate, nomlabofusp (formerly CTI-1601), is a recombinant fusion protein being evaluated in a Phase 2 clinical program for the treatment of Friedreich's ataxia, a rare and progressive genetic disease. Larimar Therapeutics plans to leverage its platform to develop additional therapies for other rare diseases characterized by deficiencies in intracellular proteins.

Recent filings

Filing Released Lang Actions
FORM 4 SUBMISSION
Director's Dealing
2016-07-01 English
FORM 8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated June 30, 2016, for Zafgen, Inc. It reports the submission of matters to a vote of security holders at the Annual Meeting, including election of directors and ratification of the independent auditor. It also details compensatory arrangements of certain officers, specifically severance and change in control agreements. The content focuses on voting results and management compensation agreements rather than financial results or full reports. The document is not an Annual Report, Earnings Release, or Interim Report. It is a current report disclosing specific corporate events and governance matters. The primary focus is on voting results and management agreements, which aligns best with the category "Declaration of Voting Results & Voting Rights Announcements (DVA)" for the voting results portion, but also includes management compensation arrangements which are typically reported in 8-Ks but do not fit other categories precisely. Since the voting results are a major part and the document is a Form 8-K current report, the best fit is DVA for the voting results disclosure. The compensatory arrangements are part of the 8-K disclosures but do not constitute a separate Remuneration Information filing (DEF 14A) or Management Report. Therefore, the classification is DVA with high confidence.
2016-07-01 English
FORM 4 SUBMISSION
Director's Dealing
2016-07-01 English
FORM 4 SUBMISSION
Director's Dealing
2016-07-01 English
10-Q
Interim / Quarterly Report Q1 2016
2016-05-10 English
FORM 8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated May 10, 2016, by Zafgen, Inc. It announces the company's financial results for the first quarter of 2016 and includes a press release as Exhibit 99.1. The text explicitly states that the press release is being furnished and incorporated by reference, and the document is a current report rather than a full financial report. The length of the document is 2859 characters, which is relatively short and consistent with an earnings release announcement rather than a full quarterly report. The key phrase 'announced its financial results for the first quarter of 2016' and the inclusion of a press release as an exhibit strongly indicate this is an Earnings Release (ER) filing. It is not a full Interim/Quarterly Report (IR) because it does not contain substantive financial statements or detailed analysis, only a press release summary. Therefore, the correct classification is Earnings Release (ER).
2016-05-10 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.